Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.

Date publication

janvier 2024

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr BERTAUT Aurélie , Dr COUDERT Bruno , Pr COUTANT Charles , Dr LADOIRE Sylvain , Dr DESMOULINS Isabelle , Dr HENNEQUIN Audrey

Tous les auteurs :
Ilie SM, Briot N, Constatin G, Ilie A, Beltjens F, Ladoire S, Desmoulins I, Hennequin A, Bertaut A, Coutant C, Causeret S, Ghozali N, Coudert B, Arnould L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38273853

Résumé

The persistence of residual tumour after neoadjuvant chemotherapy (NAC) in localised triple-negative breast cancer (TNBC) is known to have a negative prognostic value. However, different degrees of expression of some immunohistochemical markers may correlate with different prognoses.

Mots clés

immunohistochemical marker, neoadjuvant chemotherapy, prognostic biomarkers, residual disease, triple-negative breast cancer

Référence

Front Oncol. 2024 01 10;13:1309890